Literature DB >> 27511979

Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.

Thomas A Treibel1, Marianna Fontana2, Janet A Gilbertson2, Silvia Castelletti2, Steven K White2, Paul R Scully2, Neil Roberts2, David F Hutt2, Dorota M Rowczenio2, Carol J Whelan2, Michael A Ashworth2, Julian D Gillmore2, Philip N Hawkins2, James C Moon2.   

Abstract

BACKGROUND: Calcific aortic stenosis (cAS) affects 3% of individuals aged >75 years, leading to heart failure and death unless the valve is replaced. Wild-type transthyretin cardiac amyloid is also a disorder of ageing individuals. Prevalence and clinical significance of dual pathology are unknown. This study explored the prevalence of wild-type transthyretin amyloid in cAS by myocardial biopsy, its imaging phenotype and prognostic significance. METHODS AND
RESULTS: A total of 146 patients with severe AS requiring surgical valve replacement underwent cardiovascular magnetic resonance and intraoperative biopsies; 112 had cAS (75±6 years; 57% men). Amyloid was sought histologically using Congo red staining and then typed using immunohistochemistry and mass spectrometry; patients with amyloid underwent clinical evaluation including genotyping and (99m)TC-3,3-diphosphono-1,2-propanodicarboxylic-acid (DPD) bone scintigraphy. Amyloid was identified in 6 of 146 patients, all with cAS and >65 years (prevalence 5.6% in cAS >65). All 6 patients had wild-type transthyretin amyloid (mean age 75 years; range, 69-85; 4 men), not suspected on echocardiography. Cardiovascular magnetic resonance findings were of definite cardiac amyloidosis in 2, but could be explained solely by AS in the other 4. Postoperative DPD scans demonstrated cardiac localization in all 4 patients who had this investigation (2 died prior). At follow-up (median, 2.3 years), 50% with amyloid had died (versus 7.5% in cAS; 6.9% in age >65 years). In univariable analyses, the presence of transthyretin amyloidosis amyloid had the highest hazard ratio for death (9.5 [95% confidence interval, 2.5-35.8]; P=0.001).
CONCLUSIONS: Occult wild-type transthyretin cardiac amyloid had a prevalence of 6% among patients with AS aged >65 years undergoing surgical aortic valve replacement and was associated with a poor outcome.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  Congo red; aortic stenosis, calcific; aortic valve stenosis; biopsy; mass spectrometry

Mesh:

Substances:

Year:  2016        PMID: 27511979     DOI: 10.1161/CIRCIMAGING.116.005066

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  66 in total

1.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

Review 2.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

3.  Double trouble: severe aortic stenosis and cardiac amyloidosis.

Authors:  Christian Nitsche; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-12       Impact factor: 1.704

4.  Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality.

Authors:  Shivda Pandey; Omar K Siddiqi
Journal:  J Nucl Cardiol       Date:  2018-07-27       Impact factor: 5.952

Review 5.  Magnetic resonance imaging for characterizing myocardial diseases.

Authors:  Maythem Saeed; Hui Liu; Chang-Hong Liang; Mark W Wilson
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-31       Impact factor: 2.357

Review 6.  The Role of Multimodality Imaging in Transcatheter Aortic Valve Replacement.

Authors:  Qi Liu; Rebecca T Hahn
Journal:  Curr Cardiol Rep       Date:  2019-07-19       Impact factor: 2.931

7.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

Authors:  Giorgio Treglia; Andor W J M Glaudemans; Francesco Bertagna; Bouke P C Hazenberg; Paola A Erba; Raffaele Giubbini; Luca Ceriani; John O Prior; Luca Giovanella; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-23       Impact factor: 9.236

8.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.

Authors:  João L Cavalcante; Shasank Rijal; Islam Abdelkarim; Andrew D Althouse; Michael S Sharbaugh; Yaron Fridman; Prem Soman; Daniel E Forman; John T Schindler; Thomas G Gleason; Joon S Lee; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-07       Impact factor: 5.364

9.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

10.  Prevalence and prognostic impact of apical sparing contractility pattern in patients with aortic stenosis referred for transcatheter aortic valve implantation.

Authors:  Vera V Ferreira; Sílvia A Rosa; Tiago Pereira-da-Silva; Inês Rodrigues; António V Gonçalves; Tiago Mendonça; Alexandra Castelo; Luísa M Branco; Ana Galrinho; António Fiarresga; Ruben Ramos; Lino Patrício; Duarte Cacela; Rui C Ferreira
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.